Fig. 2: Temozolomide (TMZ) promotes GBM cell phagocytosis by bone marrow (BM)-derived phagocytes. | Nature Communications

Fig. 2: Temozolomide (TMZ) promotes GBM cell phagocytosis by bone marrow (BM)-derived phagocytes.

From: Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity

Fig. 2

a TMZ induces translocation of the ER chaperone calreticulin to the plasma membrane in both human and murine GBM cells in a concentration dependent manner. n = 6. b The membrane translocation of calreticulin induced by TMZ was transient, with peak occurring at 72-h post treatment. n = 6. c TMZ treatments did not result in significant membrane translocation of calreticulin in human or mouse normal bone marrow cells. d TMZ treatment promotes GBM cell phagocytosis by BM-derived phagocytes. n = 6. Unpaired Student’s t test. e TMZ treatment (50 μM) upregulated the mRNA expression of ER response-associated targets DDIT3, HERPUD1, and GADD45α in mouse GBM cells. n = 4. ** < 0.01, * < 0.05 (Unpaired Student’s t test). f Western blot showing TMZ treatment increased the expression levels of ER stress response-specific protein BiP, phospho-EIF2α, and CHOP in mouse GBM cells. TGN thapsigargin. g Addition of the ER stress inhibitor 4-PBT diminished the pro-phagocytosis and calreticulin translocation effect of TMZ. n = 6, * < 0.01 (Unpaired Student’s t test). Error bar = mean ± standard deviation.

Back to article page